Aqueous Na-ion batteries have the competitive advantages of being low costing andp ossessingi nherent safety,a nd they are particularly suitable for large-scale energy-storage applications. However,t he development of this new battery system is hindered by the lack of suitable Na hosts with sufficiently high capacity and cycle life. Herein, we report vacancy-free Na 2 CoFe(CN) 6 nanocubes synthesized by ac ontrolled crystallization reactiona nd reveal their use as an ew aqueous cathode with reversible Na-storage behavior.O wing to its perfect lattice framework with two redox-active sites, this material exhibits ah igh reversible capacity of 130 mA hg À1 ,astrong rate capability at 20 C, and superior cyclability with 90 %c apacity retention over 800 cycles,a ll of which indicatet hat this materialm ay possibly serve as ah igh-performance and long-life cathode for aqueous Na-ion batteries. Also, the synthetic strategy described in thisw ork may be extended to aw ide range of Prussian blue compounds for the fabrication of well-shaped nanocubes with few defects for energy storage, catalysis, and other applications.[a] X.
Zika virus (ZIKV) has emerged as
a global health threat due to
its unexpected causal link to devastating neurological disorders such
as fetal microcephaly; however, to date, no approved vaccine or specific
treatment is available for ZIKV infection. Here we develop a biomimetic
nanodecoy (ND) that can trap ZIKV, divert ZIKV away from its intended
targets, and inhibit ZIKV infection. The ND, which is composed of
a gelatin nanoparticle core camouflaged by mosquito medium host cell
membranes, effectively adsorbs ZIKV and inhibits ZIKV replication
in ZIKV-susceptible cells. Using a mouse model, we demonstrate that
NDs significantly attenuate the ZIKV-induced inflammatory responses
and degenerative changes and thus improve the survival rate of ZIKV-challenged
mice. Moreover, by trapping ZIKV, NDs successfully prevent ZIKV from
passing through physiologic barriers into the fetal brain and thereby
mitigate ZIKV-induced fetal microcephaly in pregnant mice. We anticipate
that this study will provide new insights into the development of
safe and effective protection against ZIKV and various other viruses
that threaten public health.
SUMMARY. Current guidelines recommend antiviral therapy for chronic hepatitis B (CHB) patients with elevated alanine aminotransferase (ALT) and high viral load. Scant histological data exist for CHB patients with persistently normal ALT (PNALT) because disease progression is thought to be rare. To identify potential predictors of significant histology in the presence of PNALT, we compared the clinical characteristics and histology of Chinese CHB PNALT patients to those in patients with elevated ALT. Percutaneous liver biopsy was performed in 522 CHB patients with Chinese ethnicity who had not had antiviral treatment. Differences in age, ALT, viral load, hepatitis B e antigen (HBeAg) status and liver histology were compared between eligible PNALT (252) and elevated ALT (270) patients. Of the PNALT patients, 38.5% had normal liver histology, 25.4% had significant necroinflammation and/or fibrosis and 8.4% had established cirrhosis. Furthermore, histopathological differences between patients with high-normal ALT (0.5-1.0 · the upper limit of normal (ULN)) and low-normal ALT (£0.5 · ULN) were evaluated. There was a significantly greater prevalence of histopathology in the high-normal group (40.0%) than in the low-normal group (16.6%) (P < 0.001). Multiple logistic regression identified that significant histopathology findings in PNALT patients correlated with age (P < 0.001) and ALT level (P < 0.001), with age >40 years and ALT >0.5 · ULN predicting significant histopathology. Our data indicate that liver biopsy is recommended in CHB patients >40 years of age, particularly when their ALT is 0.5-1.0 · ULN. The findings above provide evidence for indication of antiviral therapy in patients with PNALT and significant histopathological change.
Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is responsible for viral persistence. This study aimed to investigate the serum surrogate markers for cccDNA and to evaluate the intrahepatic viral events associated with disease activity in HBeAg-negative chronic hepatitis B patients. Thirty-three treatment-naïve patients with a negative HBeAg who had a liver biopsy were studied. Active disease was defined as a serum alanine aminotransferase >40 IU/L and a serum HBV DNA >10,000 copies/ml. This study showed significant correlation between serum HBV DNA and both log cccDNA (r = 0.41, P = 0.018) and log total intrahepatic HBV DNA (r = 0.71, P < 0.0001). No significant correlation was observed between serum HBsAg and log cccDNA (P = 0.15) or log total intrahepatic HBV DNA (P = 0.97). Fourteen and 19 patients had inactive and active disease, respectively. The median log cccDNA and log total intrahepatic HBV DNA (copies/10(6) cells) were significantly higher in patients with active disease compared with those with inactive disease (4.11 vs. 3.53, P = 0.03 and 5.46 vs. 4.64, P < 0.001, respectively). The HBV replicative efficiency, defined as the ratio of serum HBV DNA to cccDNA, was approximately 20% higher in patients with active disease. No significant difference was observed in the HBsAg levels and the ratio of serum HBsAg to cccDNA between the two groups. In conclusion, serum HBV DNA, but not HBsAg, reflects the amount of cccDNA and the replication efficiency of HBV in patients with HBeAg-negative chronic hepatitis B.
Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN add-on: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.